Answers are grounded in this paper and cite their sources.
T cells may be released in the tumor microenvironment, leaving aPD-1 to block PD-1 on T cells and generating a CUR-encapsulated cationic nanodrug that can be easily taken up by tumor cells/tumor associated macrophages (TAMs). Thus, not only the antitumor T cells mediate efficient CUR delivery to tumor but also the efficient CUR delivery promotes the tumor infiltration of antitumor T cells, thereby resulting in effective activation of antitumor immunity.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: